Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix is a one-time gene therapy administered via intravenous infusion. It is designed to deliver a functional copy of the *F8* gene to liver cells, enabling them to produce Factor VIII (FVIII) protein and reduce the frequency of bleeding in patients with hemophilia A.
## Primary Indications
Durveqtix is indicated for the prophylactic treatment of hemophilia A in adult and pediatric patients 12 years of age and older who have severe Factor VIII deficiency (FVIII activity <1%).
## Adult Dosing
The recommended dose of Durveqtix is 6 x 10^11 vector genomes per kilogram (vg/kg) administered as a single intravenous infusion.
## Pediatric Dosing
The recommended dose of Durveqtix is 6 x 10^11 vector genomes per kilogram (vg/kg) administered as a single intravenous infusion for patients 12 years of age and older. Dosing for pediatric patients younger than 12 years has not been established.
## Dose Adjustments
No dose adjustments are typically required based on renal or hepatic impairment due to the mechanism of action.
## Contraindications
Durveqtix is contraindicated in patients with known history of hypersensitivity to the active substance, any of the excipients, or any component of the formulation.
## Adverse Effects
The most common adverse reactions observed in clinical trials include:
* Infusion-related reactions (e.g., headache, nausea, vomiting, pyrexia, chills, fatigue, dizziness, muscle pain, joint pain, rash, decreased FVIII activity)
* Increased liver enzymes (ALT, AST)
* Headache
* Nausea
* Rash
## Key Drug Interactions
* **Hepatitis B vaccination:** Patients receiving Durveqtix should not receive live-attenuated hepatitis B vaccine concurrently.
* **Immunosuppressive therapy:** Concomitant use of immunosuppressive drugs may affect the durability of Durveqtix.
## Monitoring
* Monitor for signs and symptoms of infusion-related reactions during and after the infusion.
* Monitor liver function tests (ALT, AST, bilirubin) at baseline and regularly for at least 6 months post-infusion.
* Monitor FVIII activity levels as clinically indicated to assess treatment response.
* Monitor for the development of anti-drug antibodies.
## Clinical Pearls
* Durveqtix is a one-time treatment.
* Patients should be screened for pre-existing anti-adenovirus antibodies prior to administration, as high titers may reduce efficacy.
* Hepatitis B vaccination status should be reviewed and updated prior to administration.
* Long-term safety and efficacy data are still being collected.
***
**Disclaimer:** This information is intended for healthcare professional use only. Always consult the most current prescribing information and local protocols before administering any medication. Verify all doses and safety information with the official product labeling and relevant guidelines.
